Compare CubeSmart (CUBE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Regeneron Pharmaceuticals Inc — how do they compare? CubeSmart trades at $37.56 (market cap $8.38B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.1× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.69%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| CUBE | REGN | |
|---|---|---|
Market Cap | $8.38B | $76.40B |
Volume | 2,231,307 | 626,381 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $852.03 |
52-Week Low | $35.36 | $557.73 |
Typical Hold Time | 89 Days | 107 Days |
Enterprise Value | $11.91B | $71.12B |
Dividend Yield | 5.69% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.51, down 0.66% on the day, with a bearish technical signal but improving operational trends. The REIT reported Q2 2026 earnings beats and raised full-year guidance, though funds from operations slightly missed estimates. Valuation ratios like P/E of 25.33 and P/S of 7.48 are elevated, while profitability remains solid with a 29.41% net income margin. Recent news highlights institutional buying and debates on REIT valuations amid AI sector shifts.
Outlook is mixed: analyst consensus targets $44.00 with a 'Buy' lean, but technicals and macroeconomic headwinds pose risks. The stock offers a 5.4% dividend yield, yet same-store NOI declines and high debt levels warrant caution. Upside depends on sustained occupancy gains and moderating supply pressures in the self-storage sector.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
